Navigation Links
Trial to test prevention of Alzheimer's has begun
Date:9/18/2013

More than a century ago, Alois Alzheimer, a Bavarian physician, first identified the neurodegenerative brain condition that came to be known as Alzheimer's disease. Finding ways to diagnose and treat this disease has frustrated scientists and clinicians ever since.

Now the long and hard-fought campaign against Alzheimer's has reached a potentially significant milestone: the launch of the first clinical trials to test whether giving new drug treatments before dementia can prevent Alzheimer's.

Brent Whitney, 34, who has an inherited form of Alzheimer's but does not yet have symptoms of the disease, hopes to participate in the study. The lives of his grandmother and 10 of her 13 siblings were cut short by the Alzheimer's gene mutation, and the mutation continues to affect succeeding generations of the family.

"The start of this trial is a very exciting moment in Alzheimer's disease research, and it gives me renewed hope for a future without Alzheimer's," Whitney said. "I hope my grandchildren someday learn of this condition in history books, like I learned about polio."

The trial is testing two new drug treatments and is led by principal investigator Randall Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor in Neurology at Washington University School of Medicine in St. Louis and director of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU).

"We believe that the diverse portfolio of drugs and approaches of the DIAN-TU trial will accelerate the discovery of an effective treatment for Alzheimer's," Bateman said. "This trial is possible because of the outstanding support of multiple stakeholders, including patients and family members, pharma partners, the Alzheimer's Association, the National Institutes of Health, academic researchers and highly dedicated trial operations groups."

The new trial is funded by a unique mix of private and public resources, including:

  • A grant from the National Institutes of Health (NIH) for fiscal year 2013 in the amount of $1.5 million, awarded on Sept. 18, with the total amount of as much as $6 million over the four years of the project;

  • The largest Alzheimer's Association grant given to date, nearly $4.2 million;

  • Donation of the treatments used in the trials from the drugs' manufacturers, Roche and Eli Lilly and Company, which also provided major financial support for the trial;

  • Donation of a new agent for imaging brain plaques, Amyvid, by Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly; and

  • Donation by CogState of a computerized set of cognitive skills tests to help assess cognitive function in participants.

John C. Morris, MD, is director of the Charles F. and Joanne Knight Alzheimer's Disease Research Center and principal investigator of the Dominantly Inherited Alzheimer Network, which laid much of the scientific groundwork that made a DIAN-TU trial of preventive treatments possible.

"Trying to prevent Alzheimer's symptoms from occurring is a new strategy, but much of what we've learned in recent years about Alzheimer's and the brain has suggested that prevention has a significantly better chance of succeeding than treatment after cognitive impairment," said Morris, the Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology. "We are most appreciative of the support we have received to test this new approach."

For more information on the trial, see http://www.DIANXR.org.

One of the treatments under study in the new trial is gantenerumab, an antibody made by Roche that binds to all forms of aggregated amyloid beta and helps remove them from the brain.

Another treatment that will be evaluated is a monoclonal antibody known as solanezumab that binds to soluble monomeric forms of amyloid-beta after they are produced, allowing them to be cleared before they clump together to form beta-amyloid plaques.

David M. Holtzman, MD, the Andrew B. and Gretchen P. Jones Professor and head of neurology, is listed on the patent related to the antibody that is co-owned by Washington University in St. Louis and Lilly. Washington University has licensed its patent rights to Lilly. The financial interests of the university and Holtzman in this patent are managed in accordance with applicable conflict-of-interest policies and regulations.


'/>"/>

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
Source:Eurekalert

Related medicine news :

1. Brain Tumor Vaccine Shows Promise in Early Trial
2. URMC clinical trial tests new regimen for hypertension
3. Analysis Finds Clinical Trials Often Small, of Poor Quality
4. US spends far more for health care than 12 industrialized nations, but quality varies
5. New Weight-Loss Drug Shows Promise in Trial
6. Palpitations are predictive of future atrial fibrillation
7. Trial Set to See if Drug Can Prevent Alzheimers
8. Experts call for clinical trials to test non-skeletal benefits of vitamin D
9. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
10. Canada should significantly increase its funding of randomized clinical trials
11. Alzheimers vaccine trial a success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
(Date:6/23/2016)... , June 23, 2016  Experian Health, ... and transforming the patient payment and care ... innovative new products and services that will ... revenue cycle offerings. These award-winning solutions will ... workflows, remain compliant in an ever-changing environment ...
Breaking Medicine Technology: